Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LOTUS
2023-509766-37-00Phase 3Completed
- Sponsor
- Formycon AG
- Start
- Aug 2024
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 10
01
Overview
Phase 3, randomised, double-blind trial in non-squamous non-small cell lung cancer comparing FYB206 + chemotherapy with Keytruda + chemotherapy (2 arms). Started Aug 2024; status: completed.
02
Drugs
FYB206pembrolizumab
03
Conditions
non-squamous non-small cell lung cancer
Beyond the preview
Go deeper on 2023-509766-37-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-509766-37-00.